Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions

Featuring promising data on the Company’s two lead programs: BioChaperone® Lispro, partnered with Eli Lilly, and BioChaperone® Combo

Lyon, France, June 06, 2016 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced that multiple abstracts reflecting ongoing development of the ultra-rapid insulin BioChaperone® Lispro, in partnership with Eli Lilly, and BioChaperone® Combo, a unique combination of insulins glargine and lispro, have been accepted for publication and presentation at the upcoming American Diabetes Association 76th Scientific Sessions in New Orleans, LA.

Adocia and Eli Lilly will present encouraging data obtained in a BioChaperone® Lispro study during the oral session "Novel Therapeutics in Type 1 Diabetes" on Monday June 13 at 9:00 AM CT. Lead Scientist and Chairman of Profil Germany, Doctor Tim Heise, will present findings demonstrating superior postprandial blood glucose control in patients with type 1 diabetes using ultra-rapid BioChaperone® Lispro vs. Humalog®.

During the same oral session "Novel Therapeutics in Type 1 Diabetes" on Monday, June 13th at 9:15 AM CT, Doctor Steven Edelman, Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego and the Veterans Affairs Healthcare System of San Diego, will present data showing improvement of postprandial glycemia in patients with type 1 diabetes using BioChaperone® Combo vs. Humalog® Mix75/25™.

On Saturday, June 11 at 11:30 AM CT, Doctor Eda Cengiz, Assistant Professor of Pediatric Endocrinology at Yale, will present a poster discussing the pharmacodynamic profile of BioChaperone® Combo, in patients with type 2 diabetes.

Furthermore, an abstract presenting a pilot bioequivalence study comparing ultra-rapid concentrated insulin BioChaperone Lispro U200 to BioChaperone Lispro U100 (standard concentration) was also accepted for publication in Diabetes Care, the ADA journal.

Details of the four accepted abstracts on BioChaperone® Combo and BioChaperone® Lispro are presented below:

- **Oral Presentation: Ultra-Rapid BioChaperone® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog® in Subjects with Type 1 Diabetes Mellitus**

  | Abstract Number: | 294-OR |
  | Presenting Author: | Dr. Tim Heise |
  | Session: | Novel Therapeutics in Type 1 Diabetes |
  | Date and Time: | Monday June 13 from 9:00 AM – 9:15 AM CT |
  | Location: | Hall E3 |
• **Oral Presentation:** BioChaperone® Combo (BC Combo) Improves Postprandial Glycemia vs. Humalog® Mix 75/25™ (HMx) in People with Type 1 Diabetes Mellitus (T1DM)

  Abstract Number: 295-OR  
  Presenting Author: Dr. Steven Edelman  
  Session: Novel Therapeutics in Type 1 Diabetes  
  Date and Time: Monday, June 13 from 9:15 AM – 9:30 AM CT  
  Location: Hall E3

• **Poster Presentation:** Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)

  Abstract Number: 942-P  
  Presenting Author: Dr. Eda Cengiz  
  Session: 12-B Clinical Therapeutics/ New Technology-Insulins  
  Date and Time: Saturday, June 11 at 11:30 AM – 01:30 PM CT  
  Location: Poster Hall (Halls D-E)

• **Publication:** A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100

**About the ADA Scientific Sessions**

The American Diabetes Association’s Scientific Sessions is one of the industry’s premier diabetes conferences, offering researchers and health care professionals from around the globe an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment, and care. Attendees will have access to more than 2,500 original research presentations, take part in thought-provoking speaking engagements with leading diabetes experts, and expand their professional networks.

**About ADOCIA**

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaboration programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

*Adocia aims to deliver “Innovative medicine for everyone, everywhere.”*

To learn more about Adocia, please visit us at [www.adocia.com](http://www.adocia.com)
For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations Europe</th>
<th>Adocia Investor Relations USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula Chairman and CEO</td>
<td>MC Services AG Raimund Gabriel</td>
<td>The Ruth Group Tram Bui</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td><a href="mailto:raimund.gabriel@mc-services.eu">raimund.gabriel@mc-services.eu</a></td>
<td><a href="mailto:tbui@theruthgroup.com">tbui@theruthgroup.com</a></td>
</tr>
<tr>
<td>Tél. : +33 4 72 610 610</td>
<td><a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a></td>
<td>Tel.: +646.536.7035</td>
</tr>
</tbody>
</table>

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document filed with the French Autorité des marchés financiers on April 8, 2016 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.